

Tentative Agenda

Vaccines Summit-2023 | November 13-15 | Boston, MA

Keynote Presentations | **Day-1 Nov-13** |

EST (Eastern Time Zone)

Bronze Sponsor



Exhibitors



Registrations

Introduction: Opening Ceremony

Session Chair: David Weiner, Executive Vice President, The Wistar Institute, Director, Vaccine & Immunotherapy Center

- 08:00-08:30 Prospects for Vaccination against human cytomegalovirus
Stanley A. Plotkin, Consultant and Emeritus Professor of the University of Pennsylvania, Vaxconsult, LLP
- 08:30-09:00 Development of a COVID-19 vaccine
Sir Andrew J. Pollard, Ashall Professor of Paediatric Infection and Immunity and Director of Oxford Vaccine Group

- 09:00-09:30 Correlates of Protection for COVID-19 Vaccines
Dan Barouch, Director, Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center
- 09:30-10:00 Presentation Title:
Ofer Levy, Staff Physician & Principal Investigator, Director, Precision Vaccines Program, Division of Infectious Diseases, Boston Children's Hospital Professor, Harvard Medical School
Coffee Break 10:00-10:20
- 10:20-10:50 Presentation Title:
Walter Straus, Vice-President, Clinical Safety, Moderna
- 10:50-11:20 Analysis of Immunogenicity and conservation across different viral families as an approach towards pandemic preparedness
Alessandro Sette, Dr. Biol. Sci., Professor and Member, Infectious Disease and Vaccine Center, La Jolla Institute for Immunology
- 11:20-11:50
Translating Pandemic R&D Learnings into the broader global health agenda and preparedness
Sue Ann Costa Clemens, Professor of Global Health and Vaccinology at the University of Oxford and the University of Siena
- 11:50-12:20 Use of VSV vaccine platform for epidemic preparedness and response; update from current studies and innovative partnership strategies
Swati Gupta, VP, Emerging Infectious Diseases and Epidemiology, IAVI
- 12:20-12:50 NIAID, Vaccine Research Center's Pandemic Preparedness and Emergency Response: Looking at the Past to Shape Our Future
Karin Bok, Acting Deputy Director, Director of Pandemic Preparedness and Emergency Response, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Lunch Break 12:50-14:00
- 14:00-14:30 Translating the COVID-19 learnings into long-lasting innovation: how new technologies could help address global health issues and improve pandemic preparedness
Ruben Rizzi, Vice President of Global Regulatory Affairs, BioNTech
- 14:30-15:00 Ad26 viral vector based vaccines for COVID-19 and HIV-1
Hanneke Schuitemaker, VP, Head of Viral Vaccine Discovery and Translational Medicine, Janssen Vaccines and Prevention B.V
- 15:00-15:30 Developments in the Science of Vaccine Acceptance
Saad B. Omer, Founding Dean, Peter O'Donnell Jr. School of Public Health at UT Southwestern
- 15:30-16:00 Next generation mRNA Design-Increasing mRNA Potency with a New Cap Analog
Kate Broderick, Chief Innovation Officer, Maravai LifeSciences
Coffee Break 16:00-16:20

16:20-16:50 Durable Immunity, Lessons from Measles and Mumps

Richard B. Kennedy, Professor of Medicine, Co-Director, Mayo Clinic Vaccine Research Group

16:50-17:20 Presentation Title:

David Weiner, Executive Vice President, Director, Vaccine & Immunotherapy Center,
The Wistar Institute

17:20-17:50 Presentation Title:

Gary Kobinger, Director, Galveston National Laboratory

17:50-18:20 A strategic model and industry collaboration for sustainable development of vaccines against neglected diseases

Francesco Berlanda Scorza, VP, Global Health R&D Vaccines Head and GVGH Institute
Director, GSK Vaccines Institute for Global Health

18:20-19:30

Reception

18:20-19:30

Poster Presentations

Neutralization of Contemporary Omicron Subvariants after Bivalent Booster and XBB.1.5
Breakthrough Infections

Ping Ren, University of Texas Medical Branch

Neoantigen Adenoviral Cancer Vaccine Generates Improved CD8+ T-cell Responses
Compared to Conventional Peptide Vaccine

Gabriel Dagotto, Harvard University

Vaccine Countermeasure Development at the Biomedical Advanced Research and
Development

Authority (BARDA)

Rushyannah Killens-Cade, Biomedical Advanced Research and Development Authority
(BARDA)

Advanced Imaging Techniques for Pre-clinical Differentiation of Enabled Vaccine
Formulations

Michael McNevin, Merck and Co., Inc

Conjugate vaccine | DAY-2 Nov-14 | ROOM-A

Session Chair: Andrew Lees,CEO/CSO, Fina Biosolutions

- 08:00-08:30 Presentation Title: **Conjugation Chemistry, Carrier Proteins and Antigens: Promoting Conjugate Vaccine Development**
Andrew Lees,CEO/CSO, Fina Biosolutions
- 08:30-09:00 Presentation Title: **Glycoconjugate vaccines to prevent AMR pathogens**
Roberto Adamo, Vaccine Development Leader, GSK
- 09:00-09:30 Presentation Title: **A conjugate vaccines targeting a genetic form of Amyotrophic Lateral Sclerosis (C9orf72)**
Robert van der Put, Director Business Development, Scientist Process Development Conjugate Vaccines, Intravacc.nl
- 09:30-10:00 Presentation Title: **Preparation of Bacterial Polysaccharide-Protein Conjugate Vaccines**
Wei Zou, Senior Research Officer, Human Health Therapeutic Research Center, National Research Council of Canada
- Coffee Break 10:00-10:20
- 10:20-10:50 Presentation Title: **Conjugate vaccines for substance abuse**
Gary R. Matyas, Chief, Adjuvants and Formulation Section, Laboratory of Adjuvant and Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research
- 10:50-11:20 Presentation Title: **Recent advancements in the glycoconjugate vaccines field**
Francesco Berti, Senior Director, GSK Vaccines, Presentation Title: Recent advancements in the glycoconjugate vaccines field
- 11:20-11:50 Presentation Title: **Conjugation increases the immunogenicity and efficacy of T-cell inducing Glycolipid-Peptide (GLP) vaccines**
Gavin Painter, Victoria University Wellington
- 11:50-12:20 Presentation Title: **Peptide-glycolipid conjugate vaccines targeting Hepatitis B virus antigens**
Olivia Burn, Post-doctoral Research Fellow, Malaghan Institute of Medical Research
- 12:20-12:50 Presentation Title: **WISIT vaccines: Next Generation Vaccine Platform Leveraging Skin Immunity to treat chronic diseases**
Markus Mandler, Founder and CEO, of Tridem Bioscience
- Lunch Break 12:50-14:00
- 14:00-14:30 Presentation Title: **Development of a pneumococcal conjugate vaccine and novel vaccines through research driven efforts in India**
Ramesh Matur, Sr Vice President and Head – Vaccines Research & Development, Biological E Ltd

14:30-15:00 Presentation Title: **Rational design of a next-generation glycoconjugate vaccine inducing highly functional antibodies**
Giuseppe Stefanetti, Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino "Carlo Bo

Panel Session

Happy hours co-sponsored by



Coronavirus (COVID-19) | DAY-2 Nov-14 | ROOM-B

Session Chair:

- 08:00-08:20 MVA-vectored multi-antigen Covid-19 vaccines induce protective immunity against SARS-CoV-2 variants spanning Alpha to Omicron in preclinical animal models
Mukesh Kumar, Georgia State University
- 08:20-08:40 Nanoparticle intranasal vaccine prevents forward airborne transmission to naïve recipient hamsters
Jay A. Berzofsky, National Cancer Institute, NIH
- 08:40-09:00 Heterologous prime-boost immunization strategies with an orally administered aerosolized COVID-19 vaccine in China
Jingxin Li, Jiangsu Provincial Center for Disease Control and Prevention
- 09:00-09:20 Superior mucosal B- and T-cell responses against SARS-CoV-2 after heterologous intramuscular mRNA prime/intranasal protein boost vaccination with a combination adjuvant
Michael Schotsaert, Icahn School of Medicine at Mount Sinai
- 09:20-09:40 Modular Nanoarray Vaccine for SARS-CoV-2
Yuri Lyubchenko, University of Nebraska Medical Center
- 09:40-10:00 Is a long-lasting COVID-19 vaccine feasible?
Gongyi zhang, National Jewish Health
- 10:00-10:20 **Coffee Break 10:00-10:20**
- 10:20-10:40 Comparative efficacy of antiviral strategies targeting different stages of the viral life cycle
Barbara Jones, IBM Quantum

- 10:40-11:00 Intranasal Ad5 Omicron vaccine can build effective mucosal immunity wall against broad spectrum of SARS-CoV-2 variants
Ling Chen, Guangzhou Laboratory, Guangzhou Medical University
- 11:00-11:20 Prevention of Covid-19 beyond the vaccine needle: Targeting transmission via development of a novel antiviral fusion peptide-based prophylactic nasal spray
Shahin Gharakhanian, Decoy Therapeutics
- 11:20-11:40 Durable immunity to SARS-CoV-2 infection and vaccination
Mehul Suthar, Emory University School of Medicine
- 11:40-12:00 Minimalistic pan-coronavirus vaccines with a safer LNP delivery system and devoid of adverse spike epitopes
Janet K. Yamamoto, University of Florida
- 12:00-12:20 Design of a subunit precision vaccine against SARS-CoV-2
M. Dahmani Fathallah, Arabian Gulf university

Lunch Break 12:20-13:20

New Vaccine Development | DAY-2 Nov-14 | ROOM-B

Session Chair:

- 13:20-13:40 Virus/mutation-agnostic vaccines
De-chu Christopher Tang, VaxDome Inc
- 13:40-14:00 Robust Immunogenicity and Protection with PlaCCine: A Novel DNA Vaccine Delivered with a Functionalized Polymeric Delivery System
Jean D Boyer, Imunon
- 14:00-14:20 Safety profile and analytical assessment of a cross-platform trivalent combination vaccine against invasive nontyphoidal salmonellosis and typhoid fever
Francesco Citiulo, GSK Vaccines Institute for Global Health
- 14:20-14:40 Development of a broadly cross-reactive vaccine against rhinoviruses
Sebastian L. Johnston, Imperial College London
- 14:40-15:00 Interrogation of human monoclonal antibodies induced by meningococcus B vaccination to identify cross-protective antigens against gonococcus
Oretta Finco, GSK (Bacterial Vaccines Unit)
- 15:00-15:20 Correlative Outcomes of Maternal Immunization Against RSV in Cotton Rats
Jorge C. Blanco, Sigmovir Biosystems Inc.
- 15:40-16:00 CD40 ligand (CD40L)-based, dendritic cell-targeted vaccine ("FortiVac") as a platform technology for high-level CD8+ T cell responses

Coffee Break 15:20-15:40

Richard Kornbluth, Multimeric Biotherapeutics, Inc.

16:00-16:20 The Respiratory Syncytial Virus G Protein Enhances the Immune Responses to the RSV F Protein in an Enveloped Virus-like Particle Vaccine Candidate
Trudy Morrison, University of Massachusetts Chan Medical School

16:20-16:40 Vaccines and monoclonal antibodies for treatment and prevention of opioid use disorders and opioid-related overdoses
Marco Pravetoni, University of Washington School of Medicine

16:40-17:00
Thomas Tillett, MBF Therapeutics

17:00-17:20 mRNA vaccines against Lassa virus
Alexander Bukreyev, University of Texas Medical Branch

17:20-17:40 Nanoparticle-based antigen favors high level of humoral immune responses and increases antigenicity of highly glycosylated protein
Yi Yang, Hunan Agricultural University

| **DAY-3 Nov-15** | **ROOM-A**

Infectious & Non-Infectious Diseases

08:00-08:20 SchistoShield®, Sm-p80-based schistosomiasis vaccine: Human clinical trials in USA and Africa
Afzal A. Siddiqui, Texas Tech University Health Sciences Center

08:20-08:40 Development of an Effective Nontoxicogenic *Clostridioides difficile* –Based Oral Vaccine against *C. difficile* Infection
Xingmin Sun, University of South Florida

08:40-09:00 Ex vivo antigen-loading of dendritic cells as a platform for personal cancer and infectious disease vaccines
Robert O. Dillman, AIVITA Biomedical, Inc

09:00-09:20 An Ecosystem for the Rapid Generation of Biological Reagents against Infectious Diseases
Sumana Sundarmurthy, Sino Biological

09:20-09:40 DNA-based delivery of antiviral antibodies for infectious disease prevention
Rachel A. Liberatore, RenBio

09:40-10:00 Immune monitoring read outs when vector-based vaccines are used: including ELISPOT assays
Magdalena Tary-Lehmann, Cellular Technology Limited

10:00-10:20 The underlying genetic architecture of the immune system responsible for immunodominance
Stephen J Elledge, Harvard Medical School

Coffee Break 10:20-10:40

Cancer Vaccines & Immunotherapy

10:40-11:00 Preclinical Proof Of Concept Studies of a Novel Human HER-2 Virus Like Particle as a Vaccine Candidate for Human Breast Cancers
Farshad Guirakhoo, ExpreS2ion Biotechnology

11:00-11:20 Exploring T-Cell Pathways to Enhance Immunotherapies in Cancer and Infection
Christopher E. Rudd, Universite de Montreal

11:20-11:40 Stimulation of anti-tumor Responses with small molecules that induce Z-DNA
Alan Herbert, InsideOutBio, Inc

Influenza Vaccines

11:40-12:00 Approaches to enhance the generation of broadly reactive influenza-specific antibodies in newborns
Martha Alexander-Miller, Wake Forest University School of Medicine

12:00-12:20 Development of the filamentous fungus *thermothelomyces heterothallica* c1 into a next-generation production platform for human and animal vaccines
Mark Emaflarb, Dyadic International Inc

12:20-12:40 Liposome-Display of Antigens: A Powerful Approach for Vaccine Development
Jonathan Lovell, University at Buffalo

Lunch Break 12:40-14:00

Vaccine adjuvants

14:00-14:20 Immunomodulators identified via high-throughput screening enhance control of vaccine adjuvanticity
Matthew Rosenberger, University of Chicago

14:20-14:40 Adjuvantation with mRNA encoding IL-12 overcomes mRNA vaccine limitations
Byron Brook, Boston Children's Hospital

14:40-15:00 Harnessing Sustained Release Technologies to Produce Robust, Durable, and High-Quality Immunity
Eric Andrew Appel, Stanford University

15:00-15:20 mRNA vaccine against malaria tailored for liver-resident memory T cells
Gavin Painter, Victoria University Wellington

Coffee Break 15:20-15:40

HIV Vaccine

- 15:40-16:00 Induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques with protein and mRNA vaccination
Kevin O. Saunders, Duke Human Vaccine Institute
- 16:00-16:20 Vaccination with immune complexes modulates the elicitation of functional antibodies against HIV-1
Catarina Hioe, Icahn School of Medicine at Mount Sinai
- 16:20-16:40 Antiviral Vaccine Route and Form Potently Impact Immunogenicity and Efficacy
Mark Connors, NIAID/LIR
- 16:40-17:00 ultraIPVTM: An Improved Polio Vaccine
Stephen J. Dollery, Biological Mimetics, Inc

Note

Speaking slots are available

[Submit your abstract](#)

Note: This is a tentative program subject to change

